

Dear ALPE friends and families,

We at QED know that this is a challenging time for all families. We hope that you are all doing well, are safe, and are using this time to ensure the safety and well-being of your loved ones.

We are actively assessing the impact that COVID-19 may have on our work and we want to assure you that we are committed to moving forward with our program to develop infigratinib as an option for children with achondroplasia. But we also must acknowledge that we are facing unforeseen challenges with this global pandemic.

COVID-19 may cause some delays in our studies that we hope are temporary as physicians focus on fighting the virus and families stay away from hospitals for non-essential care. We remain hopeful that the clinical trial for infigratinib in achondroplasia can start in the near future, with the exact timing dependent on how this dynamic situation evolves. Our commitment is to conduct our studies in children with achondroplasia at a safe and appropriate time.

We remain committed to the achondroplasia community and, first and foremost, to the safety of any child who participates in our studies. We will keep you up to date as the situation evolves and inform you of key developments from QED.

In the meantime, we wish you well. Please stay safe.

We invite you to read a message from Neil Kumar, the CEO of BridgeBio, the parent company of QED: <https://bridgebio.com/news/an-open-letter-to-patients-and-their-families-from-bridgebio-pharma-ceo-neil-kumar>

If you would like more information, please contact [dr@bridgebio.com](mailto:dr@bridgebio.com)

Warm regards,

David, Carl, and Daniela

David Rintell, Head of Patient Advocacy  
Carl Dambkowski, MD, Chief Strategy Officer  
Daniela Rogoff, MD, Executive Medical Director